Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Roger Perlmutter
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 384
- Beta
- 0.94
- Country
- US
Financials
EIKN has only 4 quarterly periods on file — the charts below show the full history available.
Net Income
$-88.41MEBITDA
$-88.36MFree Cash Flow
$-65.21MEPS (diluted)
$-1.63Shares Outstanding (diluted)
54.15M+0.0%Operating Expenses
$88.36MCash & Debt
$531.58MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-324.25M | $-6.16 |
Valuation
EIKNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·33d ago·Neutral
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D.
View source ↗ - Newsglobenewswire.com·41d ago·Negative
Eikon Therapeutics to Participate in Investor Conferences in September 2026 MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor co…
View source ↗ - Newsmarketbeat.com·45d ago·Neutral
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 Eikon Therapeutics NASDAQ: EIKN outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen Mansfield. President, Chief Executive Officer and Board Chair Roger Perlmutter and MD Anderson Cancer Center's Vice President and Head of Clinical Development Tim Yap discussed the rationale for improving on earlier PARP inhibitor th…
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the addition of Johnny Bennett, Ph.D.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-1.74 per share
Typical surprise -67.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.63 vs $-1.58miss
- Mon, May 11$-2.46 vs $-1.47miss
- Mon, Mar 30$-27.00 vs $-3.56miss
Estimates and results for EIKN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in EIKN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.